The long range objectives of this project are to understand the mechanism by which ATP synthase complexes (F0F1 ATPases) of higher animals synthesize ATP, and the mechanism by which this process is regulated in both normal and neoplastic tissues. Studies supported by this grant, now in its 21st year, have helped play fundamentally important roles in the elucidation of the complex substructure of F1 (i.e., alpha3 beta3 gamma delta epsilon), recognition and verification of its subunit asymmetry, resolution of its 3-D structure to 3.8A, identification of subunit locations of interacting ligands, and characterization of its interaction with an ATPase regulatory peptide. Future studies will focus on novel approaches designed to elucidate the relationship of the complex structure of F1 to both its catalytic and regulatory mechanisms.
Specific aims are 6-fold: 1) Assess the functional and regulatory significance of beta subunit asymmetry within the F1 moiety of the ATP synthase complex. 2) Characterize the adenylate kinase homology regions predicted to form an ATP binding """"""""pocket"""""""" within F1 beta subunits by evaluating directly their role in nucleotide binding. 3) Establish whether critical amino acids in F1-beta subunits labelled with the heavy atom iodine lie within the adenylate kinase homology regions or within the """"""""essential amino acid rich"""""""" C-terminal region. Assess their importance for F1-beta function. 4) Determine the external accessibility of both the adenylate kinase homology regions and the """"""""essential amino acid rich"""""""" C-terminal region of F1-beta subunits before and during catalysis. 5) Characterize the interface between F0 and F1 in greater detail with the objective of identifying the subunit site of action of the novel probe diethylstilbestrol. 6) Evaluate the roles of two newly discovered """"""""regulatory"""""""" peptides of F0F1 in normal and neoplastic tissues, and identify their site(s) of action. To accomplish these goals, a combination of biochemical; molecular biological; and immunochemical technologies, all established procedures in the P.I.'s laboratory, will be employed. These ongoing studies are both necessary and fundamental to our eventual understanding of the mechanism and regulation of mitochondrial ATP synthase complexes in normal and neoplastic tissues. Five years of support is requested.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
3R37CA010951-30S1
Application #
2761650
Study Section
Special Emphasis Panel (NSS)
Program Officer
Gallahan, Daniel L
Project Start
1979-05-01
Project End
1998-11-30
Budget Start
1998-04-01
Budget End
1998-11-30
Support Year
30
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Azevedo-Silva, J; Queirós, O; Baltazar, F et al. (2016) The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside. J Bioenerg Biomembr 48:349-62
Block, Keith I; Gyllenhaal, Charlotte; Lowe, Leroy et al. (2015) Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 35 Suppl:S276-S304
Majkowska-Skrobek, Gra?yna; Augustyniak, Daria; Lis, Pawe? et al. (2014) Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. Anticancer Drugs 25:673-82
Dylag, Mariusz; Lis, Pawel; Niedzwiecka, Katarzyna et al. (2013) 3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans. Biochem Biophys Res Commun 434:322-7
Whitehurst, Christopher B; Sanders, Marcia K; Law, Mankit et al. (2013) Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. J Virol 87:5311-5
Queirós, Odília; Preto, Ana; Pacheco, António et al. (2012) Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J Bioenerg Biomembr 44:141-53
Ko, Y H; Verhoeven, H A; Lee, M J et al. (2012) A translational study ""case report"" on the small molecule ""energy blocker"" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr 44:163-70
Lis, Pawe?; Zarzycki, Marek; Ko, Young H et al. (2012) Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. J Bioenerg Biomembr 44:155-61
Blum, David J; Ko, Young H; Pedersen, Peter L (2012) Mitochondrial ATP synthase catalytic mechanism: a novel visual comparative structural approach emphasizes pivotal roles for Mg²? and P-loop residues in making ATP. Biochemistry 51:1532-46
Chen, Ying-Bei; Aon, Miguel A; Hsu, Yi-Te et al. (2011) Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential. J Cell Biol 195:263-76

Showing the most recent 10 out of 66 publications